TCGA-BH-A0HQ-01A-11R-A034-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 37
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_JUNCTION+0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.340
- ESTROGEN_RESPONSE_EARLY+0.340
- MYOGENESIS+0.220
- WNT_BETA_CATENIN_SIGNALING+0.210
- CHOLESTEROL_HOMEOSTASIS+0.180
- COAGULATION+0.170
- NOTCH_SIGNALING+0.170
- BILE_ACID_METABOLISM+0.160
- UV_RESPONSE_DN+0.160
Top 10 suppressed
- E2F_TARGETS-0.570
- INTERFERON_ALPHA_RESPONSE-0.520
- INTERFERON_GAMMA_RESPONSE-0.510
- G2M_CHECKPOINT-0.460
- MYC_TARGETS_V1-0.450
- ALLOGRAFT_REJECTION-0.420
- TNFA_SIGNALING_VIA_NFKB-0.410
- IL6_JAK_STAT3_SIGNALING-0.380
- INFLAMMATORY_RESPONSE-0.370
- MTORC1_SIGNALING-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ULC0515T_S15 | — | cohortA1 | 0.841 |
| 2 | TCGA-S3-AA14-01A-11R-A41B-07 | — | A | 0.836 |
| 3 | SRR8613781 | — | A | 0.835 |
| 4 | TCGA-B6-A0RQ-01A-11R-A115-07 | — | A | 0.832 |
| 5 | SRR10900010 | — | — | 0.820 |
| 6 | TCGA-A8-A09B-01A-11R-A00Z-07 | — | B | 0.819 |
| 7 | AUR-AEPZ-TTP1-A-1-1-R-A742-41 | — | B | 0.814 |
| 8 | 20030017.LumA | — | B | 0.811 |
| 9 | 35c6ff25-753c-4ebe-bbe7-2e7105d052e8 | — | — | 0.808 |
| 10 | ERR2208949 | — | — | 0.805 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_JUNCTION | 0.450 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.340 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.340 | Inavolisib | — uncovered |
| MYOGENESIS | 0.220 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.170 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.160 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.040 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.030 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.010 | Remibrutinib | — uncovered |